methyl 8',10-dihydroxy-5',7'-dimethoxy-4',9,9'-trioxospiro[3,4-dihydropyrano[4,3-g]chromene-2,2'-3H-benzo[f][1]benzofuran]-7-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: methyl 8',10-dihydroxy-5',7'-dimethoxy-4',9,9'-trioxospiro[3,4-dihydropyrano[4,3-g]chromene-2,2'-3H-benzo[f][1]benzofuran]-7-carboxylate
• 化学式: C₂₇H₂₀O₁₂
• 分子量: 536.4
• InChiKey: FXCBZGHGMRSWJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  164
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• COMPOSITION FOR CLEAVING AND/OR CONNECTING SINGLE STRAND DNA
  申请人：Waseda University

  公开号：EP2128250A1

  公开（公告）日：2009-12-02

  It is an object of the present invention to provide a composition for catalyzing the cleavage of a single-stranded DNA and the binding of such single-stranded DNA. The present invention provides a composition for cleaving a single-stranded DNA and/or binding the 5'-terminus of such single-stranded DNA to the 3'-terminus thereof, which comprises an Evl protein. Moreover, the present invention also provides a composition for cleaving a single-stranded DNA and/or binding the 5'-terminus of such single-stranded DNA to the 3'-terminus thereof, which further comprises a Rad51B protein and/or a DNA topoisomerase type I protein, as well as the Evl protein.

  本发明的目的是提供一种用于催化单链DNA裂解和结合这种单链DNA的组合物。本发明提供了一种用于裂解单链 DNA 和/或将该单链 DNA 的 5'- 末端与其 3'- 末端结合的组合物，该组合物包含 Evl 蛋白。此外，本发明还提供了一种用于裂解单链 DNA 和/或将该单链 DNA 的 5'- 末端与其 3'- 末端结合的组合物，该组合物进一步包括 Rad51B 蛋白和/或 DNA 拓扑异构酶 I 型蛋白以及 Evl 蛋白。
• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• TERT promoter mutations in cancer
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10544464B2

  公开（公告）日：2020-01-28

  The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain promoter mutations in cancer. In one embodiment, a method for treating a subject having thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 C>T (C228T) and 1 295 250 C>T (C250T), corresponding to −124 C>T and −146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and/or C250T mutation is identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer.

  本发明涉及癌症领域。更具体地说，本发明提供了与癌症中某些启动子突变有关的方法和组合物。在一个实施方案中，一种治疗甲状腺癌受试者的方法包括以下步骤：(a)从受试者处获得生物样本；(b)对从受试者处获得的样本进行检测，以确定1 295 228 C>T（C228T）和1 295 250 C>T（C250T）处的突变，对应于端粒酶逆转录酶（TERT）基因启动子中翻译起始位点的-124 C>T和-146 C>T；(c) 如果鉴定出 C228T 和/或 C250T 突变，则将受试者鉴定为患有或可能患有侵袭性甲状腺癌；以及 (d) 使用适合患有或可能患有侵袭性甲状腺癌的受试者的一种或多种治疗方法治疗受试者。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。